Traws Pharma, Inc. (NASDAQ: TRAW) has released its financial results for the year ending December 31, 2024, alongside ...

Traws Pharma, Inc. ( NASDAQ: TRAW) Virtual Investor Event March 31, 2025 10:00 AM ET Werner Cautreels – Chief Executive Officer Robert Redfield – Chief Medical Officer David Pauza – Chief Science ...

Tivoxavir marboxil's potential as a single dose therapeutic agent for bird flu supported by significant antiviral activity in three well accepted animal models and positive Phase 1 data Ongoing FDA ...

Tivoxavir marboxil’s potential as a single dose therapeutic agent for bird flu supported by significant antiviral activity in ...

Reports FY24 revenue $226,000 vs $226,000 last year. “I believe Traws made outstanding progress over the last year. We re-defined our focus – ...

Werner Cautreels, PhD, to retire as CEO, while continuing as a Board MemberIain D. Dukes, D Phil, Executive Board Chairman, to become Interim CEO NEWTOWN, Pa., March 28, 2025 (GLOBE NEWSWIRE) -- Traws ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Werner Cautreels, PhD, to retire as CEO, while continuing as a Board MemberIain D. Dukes, D Phil, Executive Board Chairman, ...

NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) has unveiled promising preclinical and Phase 1 data for ratutrelvir, its ...

Preclinical and Phase 1 data suggest that ratutrelvir can be used without ritonavir and may reduce the likelihood of COVID rebound and the risk ...

Potent Antiviral Activity in Preclinical Challenge Model: Results from a rodent challenge model showed that 100% of mice ...

Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.